Search results for "Migraine"

showing 10 items of 254 documents

Intracortical facilitation within the migraine motor cortex depends on the stimulation intensity. A paired-pulse TMS study

2018

Abstract Introduction Connectivity within the primary motor cortex can be measured using the paired-pulse transcranial magnetic stimulation (TMS) paradigm. This evaluates the effect of a first conditioning stimulus on the motor evoked potential (MEP) elicited by a second test stimulus when different interstimulus intervals are used. Aim of the present study was to provide, in patients suffering from migraine without aura (MwoA), additional information on intracortical facilitation (ICF), short intracortical inhibition (SICI), and long intracortical inhibition (LICI), using different intensities of the test stimulus (TS). Methods We enrolled 24 patients with episodic MwoA and 24 age- and sex…

0301 basic medicineAdultMaleMigraine without Auramedicine.medical_specialtyMotor cortex paired pulsemedicine.medical_treatmentRestlcsh:MedicineStimulationAudiologyStimulus (physiology)03 medical and health sciencesYoung Adult0302 clinical medicineHumansMedicineIctalEvoked potentialbusiness.industryElectromyographylcsh:RMotor CortexCortical excitabilityNeural InhibitionGeneral MedicineMiddle Agedmedicine.diseaseEvoked Potentials MotorTranscranial Magnetic StimulationTranscranial magnetic stimulation030104 developmental biologymedicine.anatomical_structureAnesthesiology and Pain MedicineMigraineFemaleNeurology (clinical)Primary motor cortexGlutamatebusiness030217 neurology & neurosurgeryResearch ArticleMotor cortexHuman
researchProduct

Viral encephalitis in Parry-Romberg syndrome

2019

A 28-year-old woman was admitted to our clinic for acute onset of headache, aphasia and confusion, followed by a first episode of generalised tonic–clonic seizures. She had a history of left-sided migraine, accompanied by visual aura and right arm dysesthesia since the age of 20 years and

0301 basic medicineAdultPediatricsmedicine.medical_specialtyImages In…030105 genetics & heredityinfection (neurology)03 medical and health sciences0302 clinical medicineSeizuresAphasiaFacial HemiatrophymedicineHumansEncephalitis ViralFirst episodeDysesthesianeuroimagingbusiness.industryViral encephalitisneurologymeningitisParry–Romberg syndromeGeneral Medicinemedicine.diseasenervous system diseasesMigraineFemaleSettore MED/26 - Neurologiamedicine.symptombusinessMeningitis030217 neurology & neurosurgeryEncephalitis
researchProduct

Benign nocturnal alternating hemiplegia of childhood

2018

Objective: To describe the clinical spectrum of benign nocturnal alternating hemiplegia of childhood (BNAHC) including long-term follow-up data of previously published cases and to propose an underlying genetic cause of this disorder. Methods: We studied the medical data of two novel patients, reviewed the literature on BNAHC, and gathered information of the most recent follow-up of published cases regarding the course of episodes, further development, attempted drugs, ancillary investigations, and sequelae. Results: All patients, i.e. two novel cases and twelve patients identified in the literature (13 boys, 1 girl, age at onset four months to three years), experienced episodes of hemipleg…

0301 basic medicineMaleExome sequencingPediatricsmedicine.medical_specialtyHeterozygoteHemiplegiaNerve Tissue ProteinsPATIENTSensory disorders Donders Center for Medical Neuroscience [Radboudumc 12]03 medical and health sciences0302 clinical medicinePRRT2 MUTATIONSmedicineHumansIctalPAROXYSMAL KINESIGENIC DYSKINESIAFamily historyPRRT2 geneExome sequencingCryingbusiness.industryAlternating hemiplegia of childhoodInfantMembrane ProteinsGeneral MedicineParoxysmal dyskinesiamedicine.diseaseDisorders of movement Donders Center for Medical Neuroscience [Radboudumc 3]GENESleep deprivation030104 developmental biologyPhenotypeTreatment OutcomeSYNAPTIC-TRANSMISSIONMigraineMIGRAINEChild PreschoolPediatrics Perinatology and Child HealthDisease ProgressionNeurology (clinical)medicine.symptombusinessINFANTILE CONVULSIONS030217 neurology & neurosurgeryGene DeletionBenign nocturnal alternating hemiplegia of childhoodEuropean Journal of Paediatric Neurology
researchProduct

Triptans and CGRP blockade - impact on the cranial vasculature.

2017

Abstract The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and mig…

0301 basic medicineMigraine DisordersCalcitonin gene related peptide – CGRPNeuropeptidelcsh:MedicineMigraine modelsReviewTriptansReview ArticleCalcitonin gene-related peptide03 medical and health sciences0302 clinical medicineJournal ArticlemedicineHumansMigraine treatmentReceptorbusiness.industryTriptans Calcitonin gene related peptide – CGRP Anti-CGRP (receptor) monoclonal antibodies – mAbs Middle meningeal artery Middle cerebral arteries Migraine models Magnetic resonance angiography (MRA)Anti-CGRP (receptor) monoclonal antibodies – mAbsTrigeminovascular systemlcsh:RTriptansGeneral MedicineMiddle meningeal arterymedicine.diseaseTryptamines3. Good healthMagnetic resonance angiography (MRA)Middle cerebral arteries030104 developmental biologyAnesthesiology and Pain MedicineMigraineAnesthesiaNeurology (clinical)SerotoninbusinessNeuroscience030217 neurology & neurosurgerymedicine.drugReceptors Calcitonin Gene-Related PeptideThe journal of headache and pain
researchProduct

Hypertrophic pachymeningitis and cerebral venous thrombosis in myeloperoxidase-ANCA associated vasculitis

2019

Hypertrophic pachymeningitis (HP) is a circumscribed inflammatory process that thickens meninges with fibrous adhesions. Among the causes of HP, vasculitis and autoimmune disease should be considered; myeloperoxidase (MPO)-antinuclear cytoplasmatic antibodies (ANCA)-positivity can be the only

0301 basic medicinePathologymedicine.medical_specialtyImages In…PrednisoloneAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisANCA-Associated Vasculitis030105 genetics & heredityneurootologyvasculitisAntibodies Antineutrophil Cytoplasmic03 medical and health sciences0302 clinical medicinemedicineHumansskin and connective tissue diseasesPeroxidaseAutoimmune diseaseneuroimagingbiologybusiness.industryHeadacheMeningesmeningitisGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingVenous thrombosisTreatment Outcomemedicine.anatomical_structureMyeloperoxidasebiology.proteinFemaleSettore MED/26 - NeurologiaIntracranial ThrombosisAntibodyVasculitisbusinessheadache (including migraines)MeningitisBiomarkers030217 neurology & neurosurgeryBMJ Case Reports
researchProduct

Non-Rapid Eye Movement Sleep Parasomnias and Migraine: A Role of Orexinergic Projections

2018

Introduction: Sleep and migraine share a common pathophysiological substrate, although the underlying mechanisms are unknown. The serotonergic and orexinergic systems are both involved in the regulation of sleep/wake cycle, and numerous studies show that both are involved in the migraine etiopathogenesis. These two systems are anatomically and functionally interconnected. Our hypothesis is that in migraine a dysfunction of orexinergic projections on the median raphe (MR) nuclei, interfering with serotonergic regulation, may cause Non-Rapid Eye Movement parasomnias, such as somnambulism. Hypothesis/theory: Acting on the serotonergic neurons of the raphe nuclei, the dysfunction of orexinergic…

0301 basic medicineSerotonergic systemMigraine; Orexinergic system; Pro-inflammatory peptides; Serotonergic system; Sleep-wake rhythm; Neurology; Neurology (clinical)Substance PCalcitonin gene-related peptidePro-inflammatory peptideSerotonergicNon-rapid eye movement sleeplcsh:RC346-429sleep–wake rhythmMigraine; Orexinergic system; Pro-inflammatory peptides; Serotonergic system; Sleep-wake rhythm;Settore M-PSI/04 - Psicologia Dello Sviluppo E Psicologia Dell'Educazione03 medical and health sciencesTrigeminal ganglionchemistry.chemical_compound0302 clinical medicinePro-inflammatory peptidesSleep-wake rhythmHypothesis and TheoryMedicinelcsh:Neurology. Diseases of the nervous systemMigraineMigraine; Orexinergic system; Pro-inflammatory peptides; Serotonergic system; Sleep-wake rhythmbusiness.industryOrexinergic systemserotonergic system orexinergic system sleep–wake rhythm migraine pro-inflammatory peptidesSettore MED/39 - Neuropsichiatria InfantileOrexin030104 developmental biologyNeurologychemistryNeurology (clinical)SerotoninbusinessRaphe nucleiNeuroscience030217 neurology & neurosurgeryNeuroscienceFrontiers in Neurology
researchProduct

PACAP38 and PAC1 receptor blockade: a new target for headache?

2018

Abstract Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. Moreover, PACAP38 is a potent inducer of migraine-like attacks, but the mechanism behind this has not been fully elucidated. Migraine is a neurovascular disorder, recognized as the second most disabling disease. Nevertheless, the antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are the only prophylactic treatment developed specifically for migraine. These antibodies have displayed positive results in clinical trials, but are not effective for all patients; therefore, new pharmacol…

0301 basic medicineSide effectPAC1 receptorMigraine DisordersMigraine Disorders/drug therapylcsh:MedicinePituitary Adenylate Cyclase-Activating Polypeptide/antagonists & inhibitorsReview ArticleTriptansPharmacologyCalcitonin gene-related peptidePACAPNeuroprotectionmigraine; PAC1 receptor; PACAP; prophylactic treatment; animals; disease models animal; headache; humans; migraine disorders; pituitary adenylate cyclase-activating polypeptide; receptors pituitary adenylate cyclase-activating polypeptide type I; neurology (clinical); anesthesiology and pain medicine03 medical and health sciences0302 clinical medicineAnimalsHumansMedicineMigraine treatmentReceptorMigraineHeadache/drug therapybusiness.industrylcsh:RHeadacheGeneral Medicinemedicine.disease3. Good healthBlockadeDisease Models Animal030104 developmental biologyAnesthesiology and Pain MedicineMigrainePituitary Adenylate Cyclase-Activating PolypeptideNeurology (clinical)businessProphylactic treatment030217 neurology & neurosurgeryReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type IReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type I/antagonists & inhibitorsmedicine.drugJournal of Headache and Pain
researchProduct

Hyperresponsivity in migraine: a network dysfunction or an analytic cognitive style-connected feature?

2018

not available

0301 basic medicinemedicine.medical_specialtyNeurologyMigraine DisordersDermatologyThinking03 medical and health sciencesCognition0302 clinical medicinemedicineHumansNeuroradiologyGeneral Medicinemedicine.diseasePsychiatry and Mental health030104 developmental biologyMigraineFeature (computer vision)Neurology (clinical)NeurosurgeryPsychology030217 neurology & neurosurgeryPersonality2708Cognitive psychologyCognitive styleNeurological Sciences
researchProduct

Magnesium and health outcomes: An umbrella review of systematic reviews and meta-analyses of observational and intervention studies

2020

Purpose: To map and grade all health outcomes associated with magnesium (Mg) intake and supplementation using an umbrella review. Methods: Umbrella review of systematic reviews with meta-analyses of observational studies and randomized controlled trials (RCTs) using placebo/no intervention as control group. We assessed meta-analyses of observational studies based on random-effect summary effect sizes and their p values, 95% prediction intervals, heterogeneity, small-study effects and excess significance. For meta-analyses of RCTs, outcomes with a random-effect p value < 0.005 and a high-GRADE assessment were classified as strong evidence. Results: From 2048 abstracts, 16 meta-analyses an…

0301 basic medicinemedicine.medical_specialtyUmbrella review.Settore MED/09 - Medicina InternaHealth StatusMedicine (miscellaneous)030209 endocrinology & metabolismType 2 diabetesPlaceboDiabetelaw.inventionMagnesium Meta-analysis Pregnancy Diabetes Stroke Umbrella reviewUmbrella review03 medical and health sciences0302 clinical medicineRandomized controlled triallawPregnancyInternal medicinemedicineHumansMeta-analysiMagnesiumStroke030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryDiabetesmedicine.diseaseStrokeMeta-analysisObservational Studies as TopicSystematic reviewMigraineMeta-analysisDietary SupplementsObservational studybusiness
researchProduct

Blocking CGRP in migraine patients – a review of pros and cons

2017

Abstract Migraine is the most prevalent neurological disorder worldwide and it has immense socioeconomic impact. Currently, preventative treatment options for migraine include drugs developed for diseases other than migraine such as hypertension, depression and epilepsy. During the last decade, however, blocking calcitonin gene-related peptide (CGRP) has emerged as a possible mechanism for prevention of migraine attacks. CGRP has been shown to be released during migraine attacks and it may play a causative role in induction of migraine attacks. Here, we review the pros and cons of blocking CGRP in migraine patients. To date, two different classes of drugs blocking CGRP have been developed: …

0301 basic medicinemedicine.medical_specialtyanesthesiology and pain medicineNeurologyCalcitonin Gene-Related PeptideMigraine DisordersCentral nervous systemlcsh:MedicineNeurological disorderReview ArticleCalcitonin gene-related peptidePlaceboBioinformatics03 medical and health sciencesEpilepsy0302 clinical medicineCalcitonin Gene-Related Peptide Receptor AntagonistsMedicineAnimalsHumansMigraineneurology (clinical)integumentary systembusiness.industrylcsh:Racute treatment; CGRP; CGRP receptor; gepants; migraine; prophylactic treatment; neurology (clinical); anesthesiology and pain medicineCgrp receptorGeneral MedicineGepantsmedicine.disease3. Good health030104 developmental biologymedicine.anatomical_structureMigrainenervous systemAnesthesiaAcute treatment; Cgrp; Cgrp receptor; Gepants; Migraine; Prophylactic treatment; Neurology (clinical); Anesthesiology and Pain MedicineCgrpAnimal studiesbusinessGepantProphylactic treatmentAcute treatment030217 neurology & neurosurgery
researchProduct